# Bencao Capital

> Bencao Capital is a VC fund backing Health Care, Biotechnology and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Jun 2026
- Lead investor: 40%
- Last updated: Aug 2026

Bencao Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Biotechnology | 2 | 40% |
| Medical | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Seed | 1 | 20% |
| Angel | 1 | 20% |
| Series A | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Yimou Bio | Yimou Bio focuses on the research and development of small nucleic acid drugs for ophthalmology, aiming to create innovative therapies for the treatment of eye diseases and improve patient outcomes through advanced biotechnology solutions. |  | Angel | Jun 08, 2026 |  |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $13.8M | Series A | Nov 15, 2024 |  |
| Tianhu Technology | Tianhu Technology is a computational chemistry and AI-driven innovative drug molecule design provider. | $1.4M | Seed | Apr 01, 2024 |  |
| Xiguang Bio | Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions. | $13.8M | Series B | Jul 19, 2023 |  |
| CytoNiche | CytoNiche focuses on the development of 3D micro-organization engineering technology. The core technology is derived from the transformation of Tsinghua University's achievements. Based on its original research technology, Huasheng Bio has launched a series of related products and services, including customized, large-scale, automated andintelligent stem cell culture. Amplification process; 3D stem cell micro-tissue regeneration treatment of new drugs and 3D cell high-throughput drug screening products. | $47.5M | Series B | Mar 03, 2022 |  |

5 of 5 investments shown.

## Co-investors
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 3 deals together
- [Gaorong Capital](https://shizune.co/investors/profile/banyan-capital) — VC Fund, 2 deals together
- [CICC Qide](https://shizune.co/investors/profile/cicc-qide) — VC Fund, 2 deals together
- [Aibo Qingshi Venture Capital Fund](https://shizune.co/investors/profile/aibo-qingshi-venture-capital-fund) — VC Fund, 1 deal together
- [Hongtai Capital Holdings](https://shizune.co/investors/profile/aplus-capital) — VC Fund, 1 deal together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bencao Capital invest in?

Bencao Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bencao Capital last invest?

The most recent investment recorded for Bencao Capital closed in Jun 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co